Auto-Abs neutralized by the serum from the 19 patients
| Patient . | Anti-IFN-α2 auto-Abs (10 ng/ml) . | Anti-IFN-β auto-Abs (10 ng/ml) . | Anti-IFN-ω auto-Abs (10 ng/ml) . | Anti-IFN-α2 auto-Abs (100 pg/ml) . | Anti-IFN-ω auto-Abs (100 pg/ml) . |
|---|---|---|---|---|---|
| P1 | 1 | 0 | 0 | 1 | 0 |
| P2 | 1 | 1 | 1 | 1 | 1 |
| P3 | 0 | 0 | 0 | 1 | 0 |
| P4 | 0 | 0 | 0 | 0 | 1 |
| P5 | 0 | 0 | 0 | 0 | 1 |
| P6 | 0 | 0 | 0 | 0 | 1 |
| P7 | 0 | 0 | 0 | 1 | 1 |
| P8 | 1 | 0 | 1 | 1 | 1 |
| P9 | 1 | 0 | 1 | 1 | 1 |
| P10 | 0 | 0 | 0 | 1 | 0 |
| P11 | 0 | 0 | 0 | 1 | 1 |
| P12 | 1 | 0 | 0 | 1 | 1 |
| P13 | 0 | 0 | 0 | 0 | 1 |
| P14 | 1 | 1 | 1 | 1 | 1 |
| P15 | 0 | 0 | 0 | 0 | 1 |
| P16 | 0 | 0 | 1 | 0 | 1 |
| P17 | 0 | 0 | 0 | 0 | 1 |
| P18 | 0 | 0 | 0 | 0 | 1 |
| P19 | 0 | 0 | 0 | 0 | 1 |
| Patient . | Anti-IFN-α2 auto-Abs (10 ng/ml) . | Anti-IFN-β auto-Abs (10 ng/ml) . | Anti-IFN-ω auto-Abs (10 ng/ml) . | Anti-IFN-α2 auto-Abs (100 pg/ml) . | Anti-IFN-ω auto-Abs (100 pg/ml) . |
|---|---|---|---|---|---|
| P1 | 1 | 0 | 0 | 1 | 0 |
| P2 | 1 | 1 | 1 | 1 | 1 |
| P3 | 0 | 0 | 0 | 1 | 0 |
| P4 | 0 | 0 | 0 | 0 | 1 |
| P5 | 0 | 0 | 0 | 0 | 1 |
| P6 | 0 | 0 | 0 | 0 | 1 |
| P7 | 0 | 0 | 0 | 1 | 1 |
| P8 | 1 | 0 | 1 | 1 | 1 |
| P9 | 1 | 0 | 1 | 1 | 1 |
| P10 | 0 | 0 | 0 | 1 | 0 |
| P11 | 0 | 0 | 0 | 1 | 1 |
| P12 | 1 | 0 | 0 | 1 | 1 |
| P13 | 0 | 0 | 0 | 0 | 1 |
| P14 | 1 | 1 | 1 | 1 | 1 |
| P15 | 0 | 0 | 0 | 0 | 1 |
| P16 | 0 | 0 | 1 | 0 | 1 |
| P17 | 0 | 0 | 0 | 0 | 1 |
| P18 | 0 | 0 | 0 | 0 | 1 |
| P19 | 0 | 0 | 0 | 0 | 1 |
1: neutralizing. 0: non-neutralizing.